
Brief intro:
- Author: Kan Yang, Yuhan Shi, Xiujuan Du, Jincheng Wang, Yuefang Zhang, Shifang Shan, Yiting Yuan, Ruoqing Wang, Chenhuan Zhou, Yuting Liu, Zilin Cai, Yanzhi Wang, Liu Fan, Huatai Xu, Juehua Yu, Jinke Cheng, Fei Li, Zilong Qiu
- Journal: Cell Reports
- Doi: https://www.doi.org/10.1016/j.celrep.2021.109939
- Publication Date: 2021 Nov 2
Products/Services used in the paper
Quotation shows PackGene:AAV9-hSyn-EGFP (Serotype 9, titer 8.5x 10^14 vg/ mL), AAV9-hSyn-SENP1-EGFP (Serotype 9, titer 4.1x 10^13 vg/mL), AAV9-hSyn-SENP1-C603S-EGFP (Serotype 9, titer 4.1x10^13 vg/mL), AAV9-hSyn-FMRP-EGFP (Serotype 9, titer 4x10^13 vg/mL) and AAV9-hSyn-FMRP-K88RK130R-EGFP (Serotype 9, titer 6.2x10^13 vg/mL) were purchased from Institute of Neuroscience Gene Editing Core and PackGene Bioscience, Co, Guangzhou.
Research Field:CNS
AAV Serotype:AAV9
Targeted organ:brain
Animal or cell line strain:C57BL/6N mice
Abstract
Autism spectrum disorder (ASD) is a highly heritable neurodevelopmental disorder, causing defects of social interaction and repetitive behaviors. Here, we identify a de novo heterozygous gene-truncating mutation of the Sentrin-specific peptidase1 (SENP1) gene in people with ASD without neurodevelopmental delay. We find that Senp1+/− mice exhibit core autistic-like symptoms such as social deficits and repetitive behaviors but normal learning and memory ability. Moreover, we find that inhibitory and excitatory synaptic functions are severely affected in the retrosplenial agranular (RSA) cortex of Senp1+/− mice. Lack of Senp1 leads to increased SUMOylation and degradation of fragile X mental retardation protein (FMRP), also implicated in syndromic ASD. Importantly, re-introducing SENP1 or FMRP specifically in RSA fully rescues the defects of synaptic function and autistic-like symptoms of Senp1+/− mice. Together, these results demonstrate that disruption of the SENP1-FMRP regulatory axis in the RSA causes autistic symptoms, providing a candidate region for ASD pathophysiology.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
